Impact of Metabolic Syndrome on Graft Function and Survival After Cadaveric Renal Transplantation  Esteban Porrini, MD, Patricia Delgado, MD, Celia Bigo, MD, Alejandra Alvarez, MD, Marian Cobo, MD, María Dolores Checa, MD, Luis Hortal, MD, Ana Fernández, MD, José J. García, MD, Silvia Velázquez, MS, Domingo Hernández, MD, Eduardo Salido, MD, PhD, Armando Torres, MD  American Journal of Kidney Diseases  Volume 48, Issue 1, Pages 134-142 (July 2006) DOI: 10.1053/j.ajkd.2006.04.078 Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

Fig 1 De novo PTDM-free survival. Continuous line, patients without metabolic syndrome; dotted line, patients with metabolic syndrome. Patients with PTDM at 12 months were specifically excluded. Log rank, 23.63; P ≤ 0.001. 0 = 12 months posttransplantation. American Journal of Kidney Diseases 2006 48, 134-142DOI: (10.1053/j.ajkd.2006.04.078) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

Fig 2 Allograft survival. Continuous line, patients without metabolic syndrome; dotted line, patients with metabolic syndrome. Log rank, 7.08; P = 0.008. 0 = 12 months posttransplantation. American Journal of Kidney Diseases 2006 48, 134-142DOI: (10.1053/j.ajkd.2006.04.078) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

Fig 3 Patient survival. Continuous line, patients without metabolic syndrome; dotted line, patients with metabolic syndrome. Log rank, 5.38; P = 0.02. 0 = 12 months posttransplantation. American Journal of Kidney Diseases 2006 48, 134-142DOI: (10.1053/j.ajkd.2006.04.078) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions